Terns Pharmaceuticals, Inc. (TERN)
Largest Insider Buys in Sector
TERN Stock Price History Chart
TERN Stock Performance
About Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor …
Insider Activity of Terns Pharmaceuticals, Inc.
Over the last 12 months, insiders at Terns Pharmaceuticals, Inc. have bought $5.05M and sold $4.46M worth of Terns Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Terns Pharmaceuticals, Inc. have bought $15.4M and sold $6.36M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lu Hongbo (director) — $10M. Yoon Seokho Bryan (COO and General Counsel) — $24,081. Vignola Mark J. (Chief Financial Officer) — $24,081.
The last purchase of 476,190 shares for transaction amount of $5M was made by Lu Hongbo (director) on 2024‑09‑12.
List of Insider Buy and Sell Transactions, Terns Pharmaceuticals, Inc.
| 2024-09-12 | director | 476,190 0.7471% | $10.50 | $5M | -20.08% | |||
| 2024-09-10 | Sale | Chief Financial Officer | 10,000 0.0139% | $11.00 | $110,000 | -32.24% | ||
| 2024-09-09 | Sale | director | 17,235 0.0269% | $10.00 | $172,350 | -16.45% | ||
| 2024-08-02 | Sale | director | 8,857 0.0138% | $7.50 | $66,432 | +2.14% | ||
| 2024-08-01 | Sale | director | 6,143 0.0094% | $7.68 | $47,148 | -1.93% | ||
| 2024-07-16 | Sale | 5,188 0.012% | $10.00 | $51,880 | -20.82% | |||
| 2024-07-16 | Sale | 5,188 0.012% | $10.00 | $51,880 | -20.82% | |||
| 2024-07-16 | Sale | director | 400 0.0009% | $10.00 | $4,000 | -20.82% | ||
| 2024-07-15 | Sale | 50,976 0.1182% | $10.00 | $509,760 | 0.00% | |||
| 2024-07-15 | Sale | 50,976 0.1182% | $10.00 | $509,760 | 0.00% | |||
| 2024-07-15 | Sale | director | 14,365 0.0333% | $10.00 | $143,660 | 0.00% | ||
| 2024-05-31 | COO and General Counsel | 4,791 0.0055% | $4.44 | $21,272 | +26.46% | |||
| 2024-05-31 | Chief Financial Officer | 4,791 0.0055% | $4.44 | $21,272 | +26.46% | |||
| 2024-04-03 | Sale | 10 percent owner | 138,066 0.2207% | $6.20 | $856,009 | +19.80% | ||
| 2024-04-02 | Sale | 10 percent owner | 101,480 0.1572% | $6.65 | $674,842 | +7.98% | ||
| 2024-04-01 | Sale | 10 percent owner | 181,117 0.2758% | $6.99 | $1.27M | +0.85% | ||
| 2023-11-30 | COO and General Counsel | 743 0.001% | $3.78 | $2,809 | +52.60% | |||
| 2023-11-30 | Chief Financial Officer | 743 0.001% | $3.78 | $2,809 | +52.60% | |||
| 2023-05-31 | COO and General Counsel | 9,997 0.0019% | $1.41 | $14,096 | -43.54% | |||
| 2023-05-31 | Chief Financial Officer | 9,997 0.0019% | $1.41 | $14,096 | -43.54% |
Insider Historical Profitability
| ORBIMED ADVISORS LLC | 755635 0.8896% | $5.79 | 2 | 2 | <0.0001% | |
| GORDON CARL L | 755635 0.8896% | $5.79 | 2 | 2 | <0.0001% | |
| Lu Hongbo | director | 476190 0.5606% | $5.79 | 3 | 0 | +60.25% |
| Vivo Opportunity, LLC | 10 percent owner | 268573 0.3162% | $5.79 | 1 | 3 | +0.36% |
| Yoon Seokho Bryan | COO and General Counsel | 91940 0.1082% | $5.79 | 5 | 0 | +85.92% |
Institutional Investor Ownership
| OrbiMed | $49.98M | 11.78 | 7.62M | 0% | +$0 | 0.39 | |
| Vivo Capital | $43.68M | 10.29 | 6.66M | 0% | +$0 | 3.8 | |
| Deep Track Capital Lp | $40.02M | 9.43 | 6.1M | 0% | +$0 | 0.18 | |
| Millennium Management LLC | $22.52M | 5.31 | 3.43M | +72.62% | +$9.47M | 0.02 | |
| Vr Adviser Llc | $22.37M | 5.27 | 3.41M | -24.17% | -$7.13M | 1.09 |